GL1X · GenesisL1 explorer

MolNFT v1 · #144619 · protein

Human IGG1 lacking complement-dependent cytotoxicity: HU3S193 Fc mutant K322A

6BZ4 · Immunoglobulin gamma-1 heavy chain: “Human IGG1 lacking complement-dependent cytotoxicity: HU3S193 Fc mutant K322A”. X-ray diffraction, 4 ligands (NAG, MAN, BMA), 1 pocket (best druggability 0.25). MolNFT v1 #144619 on GenesisL1: 3D…

PDB
6BZ4
Type
protein
Length
413 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Immunoglobulin gamma-1 heavy chain
UniProt
P0DOX5
Ligands
NAG, MAN, BMA, FUC
Pockets
1 · best druggability 0.25

Structure

x-ray diffraction · 2 distinct chains · 12% helix, 47% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AImmunoglobulin gamma-1 heavy chainprotein20712% helix, 48% strandP0DOX5
BImmunoglobulin gamma-1 heavy chainprotein20612% helix, 45% strandP0DOX5

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 6 copies · chains A, B
  • MAN · alpha-D-mannopyranose · sugar · 4 copies · chains A, B
  • BMA · beta-D-mannopyranose · sugar · 2 copies · chains A, B
  • FUC · alpha-L-fucopyranose · sugar · chains A
  • EDO · 1,2-ethanediol · additive · chains B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1590.250.7223empty

Interfaces

1 interface between chains.

  • A–B · 1182 Ų buried · 6 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide, 2 glycan (disulfide, N-glycosylation).

Compared structures

  • 6BZ4 · Human IgG1 lacking complement-dependent cytotoxicity: hu3S193 Fc mutant K322A · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.